James Watt, who founded BrewDog in 2007, was ejected from the auction at the eleventh hour - Ed Hill/PA James Watt has blamed BrewDog’s new American owners for leaving thousands of early investors out of pocket. The Scottish entrepreneur, who founded the craft beer business in 2007, said he was “disappointed” by Tilray Brands’ decision to wipe out BrewDog’s so-called “equity punks” in the wake of a rescue deal. Mr Watt has criticised Irwin Simon, Tilray’s chief executive, after he failed to buy back Br ...

The expansion includes new products under its Redecan and Good Supply brands, aimed at enhancing treatment options for healthcare professionals and patients.This initiative underscores Tilray’s commitment to the Australian market, a key growth area, according to Rajnish Ohri, President of International at Tilray Brands. The expanded portfolio will offer medical cannabis flower, extracts, vapes, and pastilles, enhancing access to high-potency, patient-focused solutions.While the broader market is down, with ...

Tilray stock price has just lost a key support: is a crash to $5 coming? Tilray stock price has just lost a key support: is a crash to $5 coming? Cannabis Author Crispus Nyaga Mar 19, 2026, 15:07 PM Tilray stock price has plummeted and lost crucial support as demand for cannabis companies wanes. TLRY dropped to $6.7 on Wednesday, its lowest level since August last year. It has slumped by 72% from its highest level last year. Tilray stock has slumped despite some key catalysts TLRY share price has dropped si ...

Watt stepped down as CEO later that year. His replacement James Arrow left under a year later. Watt’s fellow co-founder Martin Dickie announced his exit from the business in August last year.In January 2024, it emerged the company was to stop paying some of its hospitality staff the UK’s so-called real living wage to tackle increased costs.An open letter , posted online under the name ‘Punks With Purpose’ and signed by 76 former employees, claimed BrewDog was built around a “cult of personality” of Watt and ...

NEW YORK and SYDNEY, March 19, 2026 (GLOBE NEWSWIRE) -- Tilray Medical, a recognized global leader in medical cannabis and a division of Tilray Brands, Inc. ("Tilray") (Nasdaq: TLRY; TSX: TLRY), today announced its largest portfolio expansion in Australia to date. The expanded medical cannabis offering reinforces Tilray Medical’s long-term commitment to the Australian market and supports increased patient access to regulated, clinically supported medical cannabis products. Tilray Medical has operated in Aus ...

Is Tilray Brands (NASDAQ: TLRY) finally bouncing back? After years of poor performance, the stock has climbed 7% over the past 12 months, which isn't bad by its standards. What's more, the market cheered the company's latest financial results. And with regulatory progress in the U.S. cannabis market, some see a bright future ahead for the pot grower. However, Tilray Brands still isn't worth investing in, not even close, in my view. Here's why I'd advise anyone to stay far away. Image source: Getty Images. ...

BRECKENRIDGE, Colo., March 18, 2026 (GLOBE NEWSWIRE) -- Breckenridge Distillery, an award-winning craft distillery and spirits brand by Tilray Brands, Inc. (NASDAQ: TLRY; TSX: TLRY is excited to announce that Cheba Hut 'Toasted' Subs will roll out Breckenridge Distillery products across 18 Colorado-based Cheba Hut restaurants. This will bring Breckenridge Distillery’s award-winning Bourbon Whiskey to all participating locations, with select restaurants in Boulder, Dillon, and one Denver location also pouri ...

Core Insights - Tilray Brands is diversifying its business beyond cannabis to mitigate risks associated with market dependency and to explore new growth opportunities [2][3] Financial Performance - For the six-month period ending November 30, 2025, Tilray reported total sales of $427 million, reflecting a 4% increase year-over-year [4] - Cannabis sales accounted for only 31% of total revenue, amounting to $132 million, while the distribution business generated $159 million and beverages contributed $106 million [4] Strategic Acquisitions - Tilray has been acquiring beverage brands in the U.S. market, positioning itself for potential growth in the cannabis beverage sector if legalization occurs [5] - The effectiveness of Tilray's growth strategy through acquisitions is debated, especially given the company's recent financial losses [5][6] Industry Context - The anticipated legalization of marijuana in the U.S. has not yet materialized, impacting the growth prospects of Canadian cannabis companies like Tilray [2] - The cannabis industry is facing challenges, with some companies disappearing or becoming leaner due to the lack of market expansion [2]

Core Viewpoint - Tilray Brands, Inc. has announced an asset purchase agreement to acquire strategic assets of BrewDog in the U.S., enhancing its beverage platform and aligning with its regional craft beer strategy [1][2]. Transaction Overview - The acquisition includes BrewDog's U.S. manufacturing and brewing operation in Columbus, Ohio, three owned pubs in Ohio (Columbus, New Albany, Cleveland), one hotel in Columbus, and a flagship brewpub in Las Vegas, Nevada, along with a franchised location in Denver and a licensed location at Columbus airport. The transaction is expected to close in Q4 FY2026, pending regulatory approvals [3]. Strategic Objectives - The acquisition strengthens Tilray's U.S. beverage platform and supports its craft beer strategy across North America, leveraging BrewDog's established presence in Ohio and Las Vegas [2][6]. - Incorporating BrewDog into Tilray's craft beer portfolio broadens its footprint in the U.S. craft beer industry and enhances consumer loyalty [6]. - The acquisition facilitates regional growth and enhances Tilray's beverage network through increased production capabilities and access to critical markets [6]. - Expanding hospitality presence increases direct-to-consumer engagement and fosters experiential brand development, aiding in strategic brand portfolio expansion [6]. - The transaction aims to realize operational efficiencies and innovation opportunities across Tilray's craft beer portfolio and emerging beverage sectors [6].

Core Viewpoint - Tilray Brands is entering a strategic partnership with pharmaceutical entities in Germany to enhance its market presence and improve access to its products [1][7]. Group 1: Strategic Partnership - The partnership involves collaboration with Tilray Medical, CC Pharma, and 14U Pharma, aimed at expanding product offerings and pharmacy access [1][2]. - Effective April 1, 2026, the alliance will leverage CC Pharma's distribution network, which supports over 16,000 pharmacies in Germany [2]. Group 2: Market Position and Performance - The collaboration is expected to strengthen Tilray's position in the dynamic German healthcare market [3]. - Despite a slight downturn in the broader market, Tilray's stock is underperforming, indicating company-specific challenges [3][7]. Group 3: Recent Developments - Tilray recently launched a new American-style light beer, Pub Light, as part of its beverage portfolio expansion [4]. - The company has acquired BrewDog Brewing Australia Pty Ltd., including its Brisbane brewery and several BrewDog bar locations [4]. Group 4: Technical Analysis - The stock is trading 5.2% below its 20-day simple moving average (SMA) and 12.9% below its 50-day SMA, indicating a bearish trend [5]. - Over the past 12 months, shares have increased by 11.79%, with a neutral RSI of 40.00 and a MACD suggesting a potential bullish crossover [5][6]. Group 5: Earnings and Analyst Outlook - Tilray is expected to provide its next financial update on April 7, 2026 [8]. - The EPS estimate is a loss of 1 cent, with a revenue estimate of $203.15 million, up from $185.78 million [10]. - The stock carries a Hold Rating, with recent analyst moves including a neutral rating from Roth Capital and a lowered target to $10.00 [11]. Group 6: ETF Exposure - Tilray has significant weight in the Amplify Alternative Harvest ETF (NYSE:MJ) at 12.38%, indicating that ETF inflows or outflows could impact the stock [12].